Cargando…

A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature

Eosinophilic esophagitis (EoE) is a chronic disease, characterized clinically by esophageal disfunction. Topical corticosteroids (tCS), predominantly fluticasone and budesonide, are considered the effective first line treatment, as well as an option of maintenance therapy in EoE. The way that tCS ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Warzecha, Joanna, Dziekiewicz, Marcin, Bieńkowska-Tokarczyk, Alicja, Małecki, Maciej, Banaszkiewicz, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694526/
https://www.ncbi.nlm.nih.gov/pubmed/36431208
http://dx.doi.org/10.3390/jcm11226730
_version_ 1784837822144839680
author Warzecha, Joanna
Dziekiewicz, Marcin
Bieńkowska-Tokarczyk, Alicja
Małecki, Maciej
Banaszkiewicz, Aleksandra
author_facet Warzecha, Joanna
Dziekiewicz, Marcin
Bieńkowska-Tokarczyk, Alicja
Małecki, Maciej
Banaszkiewicz, Aleksandra
author_sort Warzecha, Joanna
collection PubMed
description Eosinophilic esophagitis (EoE) is a chronic disease, characterized clinically by esophageal disfunction. Topical corticosteroids (tCS), predominantly fluticasone and budesonide, are considered the effective first line treatment, as well as an option of maintenance therapy in EoE. The way that tCS are administered significantly affects their effectiveness. There is still no ready-to-use steroid drug to be applied topically to the esophagus in children—a few experimental viscous slurries (mainly of budesonide) have been shown in trials to be more effective than steroids administered via metered dose inhalers (MDIs) and swallowed. The best examined steroid solvent of all is sucralose, a high-intensity artificial sweetener. Although it has been shown in a critical review that it is non-toxic and safe for all consumers, there are still some concerns among patients about its potential adverse effect on humans. Due to that fact, we developed a new viscous formulation and evaluated its effectiveness in the treatment of children with EoE. In an open, prospective, single-center study, we administered our new formulation of viscous budesonide twice daily for 8 weeks in patients with an active EoE. After treatment, we performed a control gastroscopy with the collection and evaluation of histopathological samples. We have proven our formulation effectiveness at 64%, as far as histological remission is concerned. We have also shown a reduction in the mean endoscopic reference score (EREFS) from 3.1 points at the beginning of the study to 1.6 points at the end of the study. Bearing in mind how important the acceptance of the solvent is for long-time compliance, especially among children, we also decided to assess the taste of the formulation. Therefore, we asked 46 adults and 10 children to swallow a sample of the solvent and fill in a short anonymous questionnaire about its taste, smell, consistency and easiness of swallowing. General acceptance for the proprietary solvent was high, reaching 7.5/10 among adults and 6.5/10 in children. To be able to compare the results of our preliminary experience, we reviewed the studies which evaluated substances that have been used so far as steroid solvents for the treatment of EoE. The overall effectiveness of the oral viscous budesonide (OVB) ranged from 65% to 90%, which is consistent with the results obtained in our study. Unfortunately, the high heterogeneity of the studies did not allow us to draw reliable conclusions.
format Online
Article
Text
id pubmed-9694526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96945262022-11-26 A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature Warzecha, Joanna Dziekiewicz, Marcin Bieńkowska-Tokarczyk, Alicja Małecki, Maciej Banaszkiewicz, Aleksandra J Clin Med Article Eosinophilic esophagitis (EoE) is a chronic disease, characterized clinically by esophageal disfunction. Topical corticosteroids (tCS), predominantly fluticasone and budesonide, are considered the effective first line treatment, as well as an option of maintenance therapy in EoE. The way that tCS are administered significantly affects their effectiveness. There is still no ready-to-use steroid drug to be applied topically to the esophagus in children—a few experimental viscous slurries (mainly of budesonide) have been shown in trials to be more effective than steroids administered via metered dose inhalers (MDIs) and swallowed. The best examined steroid solvent of all is sucralose, a high-intensity artificial sweetener. Although it has been shown in a critical review that it is non-toxic and safe for all consumers, there are still some concerns among patients about its potential adverse effect on humans. Due to that fact, we developed a new viscous formulation and evaluated its effectiveness in the treatment of children with EoE. In an open, prospective, single-center study, we administered our new formulation of viscous budesonide twice daily for 8 weeks in patients with an active EoE. After treatment, we performed a control gastroscopy with the collection and evaluation of histopathological samples. We have proven our formulation effectiveness at 64%, as far as histological remission is concerned. We have also shown a reduction in the mean endoscopic reference score (EREFS) from 3.1 points at the beginning of the study to 1.6 points at the end of the study. Bearing in mind how important the acceptance of the solvent is for long-time compliance, especially among children, we also decided to assess the taste of the formulation. Therefore, we asked 46 adults and 10 children to swallow a sample of the solvent and fill in a short anonymous questionnaire about its taste, smell, consistency and easiness of swallowing. General acceptance for the proprietary solvent was high, reaching 7.5/10 among adults and 6.5/10 in children. To be able to compare the results of our preliminary experience, we reviewed the studies which evaluated substances that have been used so far as steroid solvents for the treatment of EoE. The overall effectiveness of the oral viscous budesonide (OVB) ranged from 65% to 90%, which is consistent with the results obtained in our study. Unfortunately, the high heterogeneity of the studies did not allow us to draw reliable conclusions. MDPI 2022-11-14 /pmc/articles/PMC9694526/ /pubmed/36431208 http://dx.doi.org/10.3390/jcm11226730 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Warzecha, Joanna
Dziekiewicz, Marcin
Bieńkowska-Tokarczyk, Alicja
Małecki, Maciej
Banaszkiewicz, Aleksandra
A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title_full A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title_fullStr A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title_full_unstemmed A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title_short A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
title_sort new viscous budesonide formulation for the treatment of eosinophilic esophagitis in children: a preliminary experience and review of the literature
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694526/
https://www.ncbi.nlm.nih.gov/pubmed/36431208
http://dx.doi.org/10.3390/jcm11226730
work_keys_str_mv AT warzechajoanna anewviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT dziekiewiczmarcin anewviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT bienkowskatokarczykalicja anewviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT małeckimaciej anewviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT banaszkiewiczaleksandra anewviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT warzechajoanna newviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT dziekiewiczmarcin newviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT bienkowskatokarczykalicja newviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT małeckimaciej newviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature
AT banaszkiewiczaleksandra newviscousbudesonideformulationforthetreatmentofeosinophilicesophagitisinchildrenapreliminaryexperienceandreviewoftheliterature